J B CHEMICALS AND PHARMA

JB Chemicals & Pharmaceuticals Limited has informed the Exchange vide letter dated July 18, 2016 regarding "Update on Order dated 8-1-2016 and 17-5-2016 passed by National Green Tribunal".

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that as per company s code of conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, the trading window for dealing in the securities of the company will remain closed from July 1, 2016 in connection with declaration of the unaudited financial results for the quarter ending on June 30, 2016 by the board of directors of the company. The opening of trading window will be intimated to the designated persons after the board meeting date for declaration of said results is finalized.

The Exchange has sought clarification from JB Chemicals & Pharmaceuticals Limited with respect to recent news item captioned Company's Panoli tablet manufacturing facility gets inspected with zero 483 by US FDA -US FDA inspected Panoli tablet manufacturing facility last week. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. JB Chemicals & Pharmaceuticals Limited has submitted their response.

The Exchange has sought clarification from JB Chemicals & Pharmaceuticals Limited, with respect to recent news item captioned "Company's Panoli tablet manufacturing facility gets inspected with zero 483 by US FDA. US FDA inspected Panoli tablet manufacturing facility last week". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the afore

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding declaration on Auditors Report.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 20, 2016 regarding Audited Financial Results for Q4 and the year 2015-16.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held May 20, 2016 has recommended a Final dividend of Re. 0.50 (25%) per equity share of FV of Rs.2 for the year 2015-16. The dividend if declared, will be paid/ despatched on August 30, 2016.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the standalone & consolidated financial results along with the Auditors Report for the period ended March 31, 2016.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Order dated January 8, 2016 of National Green Tribunal which, inter alia, directed the closure of industrial activities at Company s bulk drugs plant at Panoli, Gujarat, and various updates thereon disclosed from time to time. Further inform that the National Green Tribunal by Judgement and Order dated May 17, 2016 ( the said Order ) has not allowed the Company s Review Application. However, by Order dated May 18,2016, the National Green Tribunal has stayed the said Order for a period of 2 months to enable the Compa

J. B. Mody, D. B. Mody, S. B. Mody has submitted to the Exchange vide letter dated April 11, 2016 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange the Update on Order of National Green Tribunal

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that as per company s code of conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, the trading window for dealing in the securities of the company will remain closed from April 1, 2016 in connection with declaration of the audited financial results for the quarter/year ended on March 31, 2016 by the board of directors of the company. The opening of trading window will be intimated to the designated persons after the board meeting date for declaration of said results is finalized.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the stay on closure of bulk drugs plant of the company has been extended upto April 6, 2016.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange vide letter dated March 11, 2016 that " We refer to our disclosure under Regulation 30 of SEBI (Listing Regulations and Disclosure Requirements), 2015 made on 13-1-2016 and update thereon disclosed on 9-2-2016 and 4-3-2016. Further to the above, we wish to disclose that the direction regarding the closure of bulk drugs plant of the company has been stayed upto 18-3-2016".

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that Mr. Mahesh K. Shroff, independent director of the company, has resigned from the board of directors of the company effective from March 12, 2016 due to his health problems.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on March 11, 2016 has declared interim dividend of Rs. 4.50 per equity share of FV of Rs.2 for current financial year. The dividend will be paid/ despatched on March 29, 2016.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the company has filed the review petition before the National Green Tribunal, Pune and the direction regarding the closure of bulk drugs plant of the company has been stayed upto March 8, 2016.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that as per company's code of conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, the trading window for dealing in the securities of the company will remain closed from March 2, 2016 to March 15, 2016 (both days inclusive) in connection with the consideration and declaration of interim dividend by the board of directors of the company at its meeting to be held on March 11, 2016.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Company has fixed Record Date as March 19, 2016 for the purpose of payment of Interim dividend for FY 2015-16.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Disclosure under Regulation 30 (7) of SEBI (Listing Regulations and Disclosure Requirements), 2015

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 03, 2016, with respect to the financial Results for the quarter ended December 31, 2015.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange the Contact details of Key Managerial Personnel Pursuant to Regulation 30(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015,

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the board of directors of the company has, at its meeting held on February 03, 2016 appointed Mr. Shaukat H. Merchant as an additional director of the company. He is an independent director on the board.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended December 31, 2015.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the company has established its bulk drugs facility at GIDC Panoli and the said plant has been operating under valid environmental clearance. This facility has been accorded environmental clearance by the Ministry of Environment & Forest, Government of India.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the trading window for dealing in the securities of the company will remain closed from January 1, 2016 in connection with declaration of the unaudited financial results for the quarter ending on December 31, 2015.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the board of directors of the company, at its meeting held on November 04, 2015 has approved the acquisition of 21,94,030 (51%) ordinary shares in Biotech Laboratories (Pty.) Ltd., South Africa ( Biotech ), held by Africa Biopharma Investments (Pty.) Ltd. by a company's subsidiary, subject to necessary approvals and definitive agreements to be entered into with the seller. The company's subsidiary J.B. Healhcare Pvt. Ltd. presently holds 21,07,990 (49%) ordinary shares in Biotech, besides 175,591 Non-Redeemable Convertible P

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 04, 2015 titled " Unaudited Financial Results Q 2- 2015-16 ".

JB Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone financial results for the period ended 30-Sep-2015.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange the trading window for dealing in the securities of the company stands closed from October 1, 2015 until further notice in connection with declaration of unaudited financial results for the quarter ended on September 30, 2015.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the compensation committee of the board of directors of the company has, on September 10,2015, issued and allotted 1,025 equity shares of face value of Rs. 2 each (1,025 shares at a premium of Rs. 93 per share) to certain employees against the exercise of options granted to them pursuant to Employees Stock Option Scheme of the company.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of Minutes of Annual General Meeting of the Company held on August 19, 2015.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange about the Results of voting at the Annual General Meeting held on August 19, 2015

JB Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone financial results for the period ended 30-Jun-2015.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding press release dated August 5, 2015 on unaudited financial results for the quarter ended on June 30, 2015.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the compensation committee of the board of directors of the company has, on July 29, 2015, issued and allotted 10,725 equity shares of face value of Rs. 2 each (10,725 shares at a premium of Rs. 93 per share) to certain employees against the exercise of options granted to them pursuant to Employees Stock Option Scheme of the company.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the Notice of the Annual General Meeting of the Company to be held on August 19, 2015.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that with reference to Company's letter dated May 20, 2015 under which the Company inter alia, informed the Exchange, August 13, 2015 as the date of payment of dividend recommended by the board of directors at its meeting held on May 20, 2015.In view of change in date of the ensuing annual general meeting, Company has informed the Exchange that the said dividend, if declared, will be paid/ warrants in respect thereof will be despatched on August 25, 2015. (revised)

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Company has decided to close the Register of Members and Share Transfer Books from August 08, 2015 to August 19, 2015 (both days inclusive) for the purpose of Annual General Meeting and Declaration of Dividend.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that as per company s code of conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, the trading window for dealing in the securities of the company will remain closed from July 1, 2015 to August 9, 2015 (both days inclusive) in connection with declaration of unaudited financial results for the quarter ended on June 30, 2015.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that Pursuant to Regulation 8(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015, Code of practices and procedures for fair disclosure of Unpublished Price Sensitive Information formulated and approved by the board of directors of the company at its meeting held on May 20, 2015.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of brief particulars of the results.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Press Release issued on audited financial results for the year ended on March 31, 2015.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the company at its meeting held on May 20, 2015 has recommended a dividend of Rs. 14 per equity share of FV of Rs.2 comprising of (i) special divided of Rs. 10 per equity share, and (ii) regular dividend of Rs. 4 per equity share for the year 2014-15. The dividend if declared, will be paid/ despatched on August 13, 2015.

JB Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2015.

Jyotindra B Mody has submitted to the Exchange vide letter dated May 08, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Jay B Mehta has submitted to the Exchange vide letter dated May 08, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Pallavi B Mehta has submitted to the Exchange Vide letter dated May 08, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Bharat P Mehta has submitted to the Exchange vide letter dated May 08, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dinesh B Mody has submitted to the Exchange vide letter dated May 08, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.